tag:blogger.com,1999:blog-4908756863334307252.post123601106009487501..comments2024-01-08T14:02:59.211-08:00Comments on Brain Today: Negative Press for Alzheimer's DrugDennis Fortierhttp://www.blogger.com/profile/04495517779435972130noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-4908756863334307252.post-36988242493118070452011-04-17T11:33:35.737-07:002011-04-17T11:33:35.737-07:00There is strong evidence that poly-therapy (Namend...There is strong evidence that poly-therapy (Namenda plus a cholinesterase inhibitor) yields clear clinical benefits in all stages of Alzheimer's disease. It is not effective by itself in treating early stage AD, and it is not approved for such an indication. It was approved for pan-European use by the EU Commission in 2002, it is available in the USA, Canada, South Africa, Australia, and many parts of Asia with approval expected in Japan later this year. Clearly there are worthy clinical benefits within the approved claims.Dennis Fortierhttps://www.blogger.com/profile/04495517779435972130noreply@blogger.comtag:blogger.com,1999:blog-4908756863334307252.post-60368830958619175742011-04-17T10:11:09.822-07:002011-04-17T10:11:09.822-07:00Namenda isn't all it's cracked up to be.
D...Namenda isn't all it's cracked up to be.<br />Did anyone know that when Namenda propositioned the British government for inclusion on the national drug formulary they were turned down?<br />Why?<br />They could not prove their glutamate science. Hmmm.<br />Since Namenda is roughly 1/3 the price of Aricept (even considering generics), you would think that the British government would try to save a few bucks and add it.Dr. Ken Romeohttp://www.thealzheimersdoc.comnoreply@blogger.com